

## **Life Sciences C-Suite Leaders To Build High-Performance Leadership at Oct 21-22 Vanguard Forum**

NEW YORK — The Vanguard Group for Leadership today announced its final lineup of sessions for the virtual Vanguard Forum for Life Sciences Leaders on Oct. 21 and 22.

The Forum, chaired by Humanigen Chairman and CEO Dr. Cameron Durrant, is an invitation-only event for CEOs and their direct reports in the Life Sciences.

This year, The Forum will focus on leading through uncertainty, and catalyzing high performance for the long term.

The Forum will feature eight sessions, led by CEOs and other leadership experts.

A sampling:

- **Turning the Pandemic Challenges into Positive Change: The Opportunity to Improve from Covid**

The unique challenges of the pandemic open great opportunities — if you can find them. This workshop develops pragmatic top leadership skills to build your business in the wake of the pandemic, including rethinking strategy, processes, and talent.

***Session leaders:***

***Dr. Cameron Durrant, Chairman and CEO, Humanigen;***

***Jason Grenfell-Gardner, Chairman, Pfenex***

- **If diversity drives performance, how do you achieve it?** In addition to contributing to societal good, diverse companies are 35% more likely to outperform their less diverse competitors. But how do you make diversity, equity and inclusion actually happen in your teams, particularly given the relative lack of diversity in the current life sciences pipeline? We'll assess the real-world challenges, and hear from colleagues who have implemented strategies that worked.

***Session leaders:***

***Stephen Brengle, Principal, Korn Ferry;***

***Michael Hyter, Chief Diversity Officer, Korn Ferry;***

***Dr. Charlotte Jones-Burton, Vice President, Otsuka Pharmaceutical***

- **What do investors want from you now?** This session is an opportunity to consider what your investor narrative will be — and what your investors will be expecting — in six months' time. In this period, it will be critical to effectively communicate the strategy and execution of the leadership team. Now more than ever, we face a tension between investor expectations of certainty and the uncertainties of real-world business. We'll bring perspectives of investors, advisors, and experienced CEOs to bear on what will work best, and what will not.

***Session leaders:***

***Daniel Eramian, Co-Founder, Opus Biotech;***

***Mike Gaffney, Managing Director, Bancroft LLC;***

***Rick Heinick, Founder and Board Chair, TearClear***

Vanguard Forums are produced by the Vanguard Group's membership organization, the Vanguard Network, which supports C-suite leaders and other top executives in honing their leadership capabilities. Vanguard collaborates with the Aspen Institute.

Vanguard's roster of more than 100 faculty and session leaders include David Pyott (Royal Dutch Philips), Ashley McEvoy (J&J), and Tom Sabatino (past GC of Aetna, Hertz and Walgreens).

Ken Banta, the Vanguard Group's founder and principal, is a top management advisor who works with CEOs and senior executives on leadership, organizational transformation and corporate positioning. Ken has helped to lead eleven successful global transformations and turn-arounds, and has advised on many more. Ken writes regularly for HBR and is a Contributing Author of "HBR's 10 Must Reads for CEOs."

For more information about the Vanguard Group for Leadership, visit <https://www.thevanguardgroupforleadership.com>.

Contact

Irene Silber

Associate Principal

The Vanguard Group for Leadership

[irene@vanguardgroup.nyc](mailto:irene@vanguardgroup.nyc)

(612) 516-6068